This study revealed NRF2 as an important factor in each of four independent long-term cisplatin treated (LTT) urothelial carcinoma cell lines (UCCs), fitting the established notion of NRF2 as a generally important factor in the development of chemoresistance and as a rational target to restore chemosensitivity [39]. The gene discussed is NFE2L2; the disease is urothelial carcinoma.